FDA clears redesigned mammography platform from Siemens Healthineers

Siemens Healthineers has obtained U.S. Food and Drug Administration clearance for its Mammomat B.brilliant, a complete rebuild of its mammography platform, designed to improve patient comfort. This marks the first major redesign from Siemens in over a decade. 

Patient comfort is prioritized through features like the ComfortPackage, including ergonomic hand grips, optimized face shields, ambient light displays, and personalized breast compression paddles. For technologists, enhancements such as a prominent display monitor, automated ComfortMove ergonomic feature and laser positioning guide aim to reduce physical strain.

“We believe more women deserve access to next-generation screening technology, and this innovation underlies our commitment to women’s health,” Niral Patel, vice president of X-ray Products at Siemens Healthineers North America said in a statement sent to Health Imaging.

Submitted for additional clearance is a 3D tomosynthesis technology that promises improved depth resolution and tissue separation through innovative detector and X-ray tube designs, as well as UltraHD reconstruction technology for enhanced imaging capabilities. Once cleared, it will be part of the Mammomat B.brilliant platform.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.